Tag Archives: announcement

RESI San Diego: Venture Philanthropy Panel Announcement

18 May

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Investors in venture philanthropy, such as foundations and specific family offices, have deep expertise that is often overlooked. Many venture philanthropic groups have a specific mission in a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking “positively impactful” technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.

LSN is pleased to announce a panel of five expert venture philanthropic investors for the RESI San Diego Conference on June 19th. The audience will have an exclusive opportunity to hear from:

Venture philanthropy investors maintain the genuine purpose of moving forward in the field of life science. Non-traditional investors such as these groups are great funding sources with incredible knowledge in their fields, while also taking inspirational strides to achieve their goals. Be sure not to lose track of the mission in life science, and not miss the opportunity of hearing how these panelists can help you with your philanthropic mission.

Register by Friday to save $200, be the first to request investor meetings on partnering, and hear from this fantastic panel!

Tags: , , , ,

RESI San Diego Agenda Announcement

20 Apr

By Michael Quigley, VP of Market Research, LSN

mike-2

For its first trip to San Diego, the Redefining Early Stage Investments (RESI) conference team will be bringing with it a content rich agenda. RESI’s Biotech and Medtech tracks will feature over 75 investor speakers across 16 panels devoted to specific investor types, technology sectors, or new issues in fundraising. Representatives from family offices, big pharma, VC, angels and more will share with the audience the types of opportunities they are currently looking for as well as what it is like to be on the other side of the negotiating table.

RESI’s Early Stage Workshops track features 4 entrepreneur education workshops, including a new session on 505(b)(2) Strategy led by Ken Phelps, CEO of Camargo.

With our Asia-North America Track, one of our newer and most popular additions, attendees will get the chance to hear directly from investors and strategic partners from across the Pacific looking for North American innovation. These panels will be a must-see for any fundraising entrepreneur in the sector.

We are very excited to bring this diverse pool of investors and speakers to San Diego to share their expertise and experience with the hundreds of fundraising scientist-entrepreneurs who attend RESI. While many of our speaking spots are already allocated, if you or someone you know would want to participate please don’t hesitate to reach out.

Tags: , , , ,

RESI on MaRS Innovation Challenge – Winners Announced

6 Apr

By Nono Hu, Director of Marketing, LSN

On April 4, more than 600 entrepreneurs and investors entered the exhibition hall at MaRS Discovery District in Toronto. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Steadiwear

Steadiwear inc.‘s mission is to restore independence and quality of life to all tremor sufferers worldwide. We have developed the Steadiglove, a smart glove that responsively stabilizes hand tremors in Essential Tremor and Parkinson’s disease using novel vibration damping technology. This allows users to go about all daily activities such as eating and getting dressed with significantly less frustration.

Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Second Place: BlueLight

BlueLight is a healthcare technology company specializing in the measurement of light energy. Our data-driven technologies, sold worldwide, target a quality gap in the multi billion-dollar dental composite market.

Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation | Michael Quigley, VP of Market Research, Life Science Nation | JP Furey, CEO, BlueLight | Peter MacLareN, Director of Customer Relations, BlueLight

Third Place: Cyclica

Cyclica Inc. has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities.

Michael Quigley, VP of Market Research, Life Science Nation | Naheed Kurji, President and CEO, Cyclica | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation

Thank you to all who competed in the RESI on MaRS Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Tags: , , , ,

RESI Panel Announcement – Diagnostic Investors

30 Mar

By Lucy Parkinson, Director of Research, LSN

Diagnostics is a challenging landscape for fundraising and commercialization; however, the sector attracts interest and backing from a wide variety of stakeholders. There are many unmet needs in the sector, from finding new disease biomarkers to improving monitoring of progressive diseases.

The range of diagnostic investors attending RESI on MaRS next Tuesday provide testament to this varied landscape, with interest in novel diagnostic technologies coming from major pharma and device companies, diagnostic service providers, venture investors, and government organizations. RESI will bring the diagnostics world together for a panel discussion, moderated by Bob Williams, Vice President, Business Development and Innovation – Bracco Diagnostics, and featuring:

These investors will introduce their own specific angle on the diagnostics sector, and will cover what they look for in an investment opportunity in this sector. Panelists will also provide advice on how to make a new diagnostic catch their attention as an investable product. If you’d like to hear the advice of these experts at RESI, there’s still time to sign up.

Tags: , , , , , ,

RESI@MaRS Panel Announcement: Early Stage Therapeutic Investors

9 Mar

By Christine A. Wu, Senior Research Analyst, LSN

chrsitine

Despite therapeutic companies’ high-risk development timeline, investors continue to remain focused on investing in biotechnology, seeing its long-term impact and enormous potential in the healthcare industry. Along with the technology, entrepreneurs need to also consider capital intensity, fundraising and milestone timeline, management team, and endpoint selections, among other topics beyond the science.

LSN has assembled five active investors specifically interested in early-stage biotech therapeutics for RESI Toronto, occurring on April 4th. Held in the heart of Canada’s healthcare innovation hub, MaRS Discovery District.

The Early Stage Therapeutic Investors Panel will be moderated by Mark Day, Head, CNS Virtual Discovery of Purdue Pharma, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the investment trends; the investor’s perspective when approaching a deal in a high-risk space; and note-worthy advice to entrepreneurs on the best way to approach and work with investors such as themselves.09

This is a tremendous opportunity for biotech life science entrepreneurs and investors to meet and develop relationships in person. Register for RESI@MaRS now so you don’t miss the chance.

Tags: , , , , , ,

RESI on MaRS Panel Announcement: Corporate Venture Capital

2 Mar

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the second time and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by John Gustofson, Senior Director, Abbvie Ventures, this panel will feature:

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

Tags: , , , , , , ,

RESI on MaRS: Full Agenda Announced

9 Feb

By Michael Quigley, VP of Market Research, LSN

mike-2

As RESI prepares for its second landing on MaRS on April 4th, the team at Life Science Nation is proud to announce the RESI investor panel agenda. With three tracks of panel and workshop content, RESI will feature a wealth of speakers representing all categories of life science investors, from family offices to VCs and angels to big pharma. These panels are a must-see for any fundraising entrepreneur in the sector.

New to Toronto this year LSN will be bringing our latest and highly popular Asia-North America Panel Track, featuring 15 speakers representing Asia based firms seeking to invest in and/or acquire North American life science companies. Entrepreneurs can hear from real investors who are  driving the increase in transpacific investments. See if your technology fits their mandate!

We are excited to be bringing these diverse investor groups into the flourishing innovation hub of Toronto and granting them a unique look into Canada’s innovative healthcare scene. Stay tuned for updates as we continue to confirm speakers and announce panels.

resi-on-mars-agenda

Tags: , , ,

← Older Entries
Newer Entries →